{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:16:54Z","timestamp":1793819814623,"version":"4.6.1"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.1001\/jamaneurol.2021.4893","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T11:04:51Z","timestamp":1641812691000},"page":"121","source":"Crossref","is-referenced-by-count":200,"title":["Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis"],"prefix":"10.1001","volume":"79","author":[{"given":"Simon","family":"Witzel","sequence":"first","affiliation":[{"name":"Department of Neurology, Ulm University, Ulm, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Maier","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Centre for ALS and other Motor Neuron Diseases, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Steinbach","sequence":"additional","affiliation":[{"name":"Thuringian Neuromuscular Center, Department of Neurology, University Hospital Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Grosskreutz","sequence":"additional","affiliation":[{"name":"Precision Neurology, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Sarikidi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Petri","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"G\u00fcnther","sequence":"additional","affiliation":[{"name":"Department of Neurology, Technische Universit\u00e4t Dresden, Dresden, Germany"},{"name":"DZNE, Site Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Neurology, Diakonissenkrankenhaus, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hermann","sequence":"additional","affiliation":[{"name":"Translational Neurodegeneration Section \u201cAlbrecht Kossel,\u201d Department of Neurology, University of Rostock, Rostock, Germany"},{"name":"DZNE, Site Rostock\/Greifswald, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Prudlo","sequence":"additional","affiliation":[{"name":"DZNE, Site Rostock\/Greifswald, Rostock, Germany"},{"name":"Department of Neurology, University Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Cordts","sequence":"additional","affiliation":[{"name":"Department of Neurology, Technical University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lingor","sequence":"additional","affiliation":[{"name":"Department of Neurology, Technical University Munich, Munich, Germany"},{"name":"DZNE, Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang N.","family":"L\u00f6scher","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zacharias","family":"Kohl","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medicine Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ruckes","sequence":"additional","affiliation":[{"name":"University Medical Center of the Johannes Gutenberg-University, Interdisciplinary Center for Clinical Trials (IZKS), Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Koch","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Centre for ALS and other Motor Neuron Diseases, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Spittel","sequence":"additional","affiliation":[{"name":"Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelia","family":"G\u00fcnther","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Michels","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ulm University, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Dorst","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ulm University, Ulm, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Meyer","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Centre for ALS and other Motor Neuron Diseases, Berlin, Germany"},{"name":"Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C.","family":"Ludolph","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ulm University, Ulm, Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"German Motor Neuron Disease Network (MND-NET)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"noi210085r1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis.","volume":"377","author":"Brown","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"noi210085r2","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/ene.v28.4","article-title":"Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: utilization and survival rates in a cohort study over 12 years in Germany.","volume":"28","author":"Spittel","year":"2021","journal-title":"Eur J Neurol"},{"issue":"9","key":"noi210085r3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis.","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med"},{"issue":"4","key":"noi210085r4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/17482960600881870","article-title":"Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study).","volume":"7","author":"Yoshino","year":"2006","journal-title":"Amyotroph Lateral Scler"},{"issue":"2","key":"noi210085r5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.expneurol.2008.07.017","article-title":"Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice.","volume":"213","author":"Ito","year":"2008","journal-title":"Exp Neurol"},{"key":"noi210085r6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.brainres.2011.01.058","article-title":"Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger.","volume":"1382","author":"Aoki","year":"2011","journal-title":"Brain Res"},{"key":"noi210085r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116906","article-title":"Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients.","volume":"415","author":"Ohta","year":"2020","journal-title":"J Neurol Sci"},{"issue":"8","key":"noi210085r8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3109\/00207454.2014.959121","article-title":"Edaravone\u2019s free radical scavenging mechanisms of neuroprotection against cerebral ischemia: review of the literature.","volume":"125","author":"Ren","year":"2015","journal-title":"Int J Neurosci"},{"issue":"7-8","key":"noi210085r9","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.","volume":"15","author":"Abe","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"7","key":"noi210085r10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.","volume":"16","author":"Abe","year":"2017","journal-title":"Lancet Neurol"},{"issue":"sup1","key":"noi210085r11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/21678421.2017.1361442","article-title":"Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis.","volume":"18","author":"Takahashi","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"sup1","key":"noi210085r12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/21678421.2017.1365372","article-title":"Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.","volume":"18","author":"Takei","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"2","key":"noi210085r13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/mus.v61.2","article-title":"Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19).","volume":"61","author":"Shefner","year":"2020","journal-title":"Muscle Nerve"},{"key":"noi210085r14","author":"Tanaka","year":"2016","journal-title":"Neurology"},{"key":"noi210085r15","doi-asserted-by":"publisher","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener","DOI":"10.1080\/21678421.2017.1363780"},{"issue":"7-8","key":"noi210085r16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/21678421.2017.1369125","article-title":"July 2017 ENCALS statement on edaravone.","volume":"18","author":"Al-Chalabi","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"noi210085r17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/14737175.2019.1581610","article-title":"Edaravone for the treatment of amyotrophic lateral sclerosis.","volume":"19","author":"Yoshino","year":"2019","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"noi210085r19","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.clinthera.2015.05.514","article-title":"Impact of postapproval evidence generation on the biopharmaceutical industry.","volume":"37","author":"Milne","year":"2015","journal-title":"Clin Ther"},{"issue":"20","key":"noi210085r20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"noi210085r22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"1","key":"noi210085r23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications.","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"noi210085r24","doi-asserted-by":"publisher","DOI":"10.1007\/s12525-021-00461-8","article-title":"Multi-sided platform and data-driven care research.","author":"F\u00fcrstenau","journal-title":"Electron Markets"},{"issue":"387","key":"noi210085r25","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1984.10478078","article-title":"Reducing bias in observational studies using subclassification on the propensity score.","volume":"79","author":"Rosenbaum","year":"1984","journal-title":"J Am Stat Assoc"},{"issue":"11","key":"noi210085r26","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1007\/s00415-020-09993-z","article-title":"The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis.","volume":"267","author":"Lunetta","year":"2020","journal-title":"J Neurol"},{"key":"noi210085r27","doi-asserted-by":"publisher","author":"Kuss","journal-title":"Dtsch Arztebl Int","DOI":"10.3238\/arztebl.2016.0597"},{"key":"noi210085r28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ensci.2018.05.001","article-title":"Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis.","volume":"11","author":"Okada","year":"2018","journal-title":"eNeurologicalSci"},{"key":"noi210085r29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jns.2019.06.006","article-title":"Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy.","volume":"404","author":"Fortuna","year":"2019","journal-title":"J Neurol Sci"},{"issue":"3-4","key":"noi210085r30","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/21678421.2019.1572191","article-title":"Early post-marketing experience with edaravone in an unselected group of patients with ALS.","volume":"20","author":"Abraham","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"10","key":"noi210085r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.14645","article-title":"Assessment of use and safety of edaravone for amyotrophic lateral sclerosis in the Veterans Affairs health care system.","volume":"3","author":"Vu","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7-8","key":"noi210085r32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/21678421.2018.1517179","article-title":"Is edaravone harmful? (a placebo is not a control).","volume":"19","author":"Turnbull","year":"2018","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"9","key":"noi210085r33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1474-4422(20)30265-9","article-title":"Reappraisal of an ALS trial: unaccounted procedural risk.","volume":"19","author":"Turnbull","year":"2020","journal-title":"Lancet Neurol"},{"key":"noi210085r18","unstructured":"European Medicine Agencies. Withdrawal assessment report: Radicava. May 24, 2019. Accessed May 26, 2021. https:\/\/www.ema.europa.eu\/en\/documents\/withdrawal-report\/withdrawal-assessment-report-radicava_en.pdf"},{"key":"noi210085r21","unstructured":"Thoemmes? F. Propensity score matching in SPSS. January 2012. Accessed May 26, 2021. https:\/\/ui.adsabs.harvard.edu\/abs\/2012arXiv1201.6385T"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2787473\/jamaneurology_witzel_2022_oi_210085_1654700180.46665.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T11:17:18Z","timestamp":1655119038000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2787473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2021.4893","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}